Chuangyebang was informed that recently, BoomRay Pharmaceuticals, which focuses on the development of a new generation of targeted nuclide conjugated drugs, announced the completion of nearly 300 million yuan in Series A financing. This financing was led by Sequoia China, with participation from Sunshine Ronghui, Tianfu Sanjiang Capital, PricewaterhouseCoopers, Qingpine Capital, Life Garden Ventures and Shenzhen Jinsheng. Ekai Capital acted as the exclusive financial advisor to WuXi vPro in this transaction.
After this financing, the company will accelerate the clinical development and registration of multiple self-developed pipelines, and accelerate the construction of R&D centers and production bases, as well as global BD cooperation.
WuXi vPro was co-incubated and established in 2018 by WuXi AppTec with the help of the Sunan Research Institute of Molecular Engineering of Peking University. The company makes full use of the basic research results of Peking University, and is committed to building a new generation of radioactive targeted drug R&D, production and clinical application platforms. The products currently deployed by the company are all independently developed and have global intellectual property rights. The company’s R&D pipeline includes multiple FIC/BIC nuclide conjugated drugs and neutron capture therapy drugs, involving multiple different indications including head and neck tumors, brain tumors, pancreatic cancer, rectal cancer, prostate cancer and inflammatory cancer identification and other diagnostic and therapeutic products.
Dr. Jiangbin Hu, Chairman and CEO of WuXi vPro, said: “Malignant tumors are still one of the most important diseases threatening human health. The annual number of new cancer patients and the total number of deaths in my country are among the highest in the world, and mankind is in the process of conquering cancer. There is a long way to go. Due to the characteristics of nuclide drugs and relatively high industry barriers, there is a big gap between my country and Europe and the United States in this field. WuXi Bo Rui hopes to develop a new generation of targeted nuclide conjugates with independent IP as soon as possible Drugs provide new diagnostic and therapeutic methods for conquering tumors.”
Prof. Zhibo Liu, Deputy Director of the Department of Applied Chemistry, School of Chemistry, Peking University and Chief Scientific Officer of WuXi BoRui, said: “When I first came into contact with nuclear drugs, I was attracted by its integrated diagnosis and treatment characteristics and unique killing mechanism. Nuclear drugs attracted me. As a once unpopular research field, we have been looking forward to cooperating with the pharmaceutical industry to promote its clinical translation while immersing ourselves in research. Thanks to the support of Peking University and the recognition of clinical experts, we have taken the first step. In the future, I believe WuXi vPro will further accelerate the technological breakthrough and clinical application of nuclear drugs in new targets, new carriers and new platforms. Finally, I would like to thank Sequoia China and other investment institutions for their support and affirmation of China’s original nuclear drugs. “
Dr. Feng Yu, the company’s vice president of R&D, also said: “The industry development of nuclide drugs in my country is currently at a critical inflection point. After the completion of this round of financing, my team and I will do our best for the clinical transformation and early listing of the company’s products. effort.”
Ms. Yang Yunxia, Partner of Sequoia China, said: “Sequoia China has always been committed to investing in companies with distinctive technical characteristics and high growth potential in the medical and health field. As a radionuclide targeted drug R&D company with original innovation capabilities, WuXi BoPro The team has rich research experience and is very distinctive in the transformation of innovative technologies, the establishment and promotion of self-developed pipelines, etc. We look forward to the early launch of its new generation of radioactive targeting nuclide-conjugated drugs to benefit patients around the world.”
Mr. Shi Shenghao, a partner of Sunshine Ronghui Capital, said: “Therapeutic nuclide-conjugated drugs have developed rapidly in recent years and are in the ascendant. They have initially proved their huge potential in clinical and commercial fields. With the maturity of the industry, with the integration of diagnosis and treatment With the special advantages of chemical technology, this field will usher in an explosion. With the team’s years of accumulation in the field of nuclear drugs, WuXi Bo Rui has a bright spot in target selection, drug design, and pipeline matching. Ronghui Capital is very pleased to participate in this round of financing. Looking forward to creating the future together with the company.
media coverage
Yiou Venture Capital Investment Circle
Related events
- “WuXi Bo Rui” completed nearly 300 million yuan in Series A financing, led by Sequoia China2022-09-02
- AI pharmaceutical company Jingtai Technology has raised more than 700 million US dollars in one year, and its post-investment valuation has exceeded 13 billion yuan2021-08-11
- AI drug development company Jingtai Technology announces strategic investment in PhoreMost 2021-03-24
- Xingkangyuan neoX completes US$30 million in Series A financing to accelerate the preclinical development of multiple innovative drugs2021-02-02
- Xing Kangyuan completes 10 million US dollars of Pre-A round of financing2020-07-06
This article is reprinted from: https://readhub.cn/topic/8iYyW1hEvWT
This site is for inclusion only, and the copyright belongs to the original author.